
TiumBio Co., Ltd.
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
321550 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
- Website:
- http://www.tiumbio.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
TiumBio Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutics for rare and incurable diseases. The company leverages its expertise in both small-molecule synthetic drugs and biologics to build a robust pipeline targeting areas with high unmet medical needs and significant growth potential. Its lead clinical programs include Merigolix (TU2670), an oral GnRH antagonist for treating gynecological conditions like endometriosis and uterine fibroids, and TU7710, a long-acting recombinant protein for hemophilia. Founded in 2016, TiumBio is also expanding its R&D capabilities into next-generation therapies, including bispecific antibodies and antibody-drug conjugates (ADCs), to create market value through its distinct portfolio.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for TiumBio Co., Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |